Aurora Health Care, which treats roughly 8,000 new cancer cases a year, launched its precision medicine program and molecular tumor board in March 2017. Before embarking on the project, the organization undertook significant preplanning and goals assessment.
As Aurora Cancer Care’s Vice President Jim Weese, MD, will explain in this session, anticipating and demonstrating the "value" of a precision medicine program can be an even greater task than executing the program. Fortunately, we can defined value in several ways - financially, as well as precision medicine’s impact to providers and patients.
Initially anticipating the tumor board to evaluate 50 patients within the first calendar year, Auurora hit this mark within four months and currently has more than 50 patients per month. Approximately 45% of patients evaluated receive evidence-based recommendations provided to their oncologist.
As Weese will explain, if you can’t show value, precision medicine is little more than an expensive commodity.
• An organization must understand financial value, including the cost of the targeted therapies, program infrastructure, access to clinical trials, patient volumes and financial assistance programs.
• Value from the physician’s perspective is critical. Efficiency in the delivery of innovative care adds a dimension to treatment not generally experienced in a community based cancer program.
• Patients worry about cost, side effects and quality of life. “Like Patient” analysis has extraordinary value when considering drugs with a positive result for patients, but perhaps more importantly in avoiding those that have not to work in similar patients.